News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NextCODE, University College Dublin's Acord Take Aim At Genetic Causes Of Autism And Rare Diseases



7/7/2014 9:18:04 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., July 7, 2014 /PRNewswire/ -- NextCODE Health, which puts whole-genome analysis in the hands of clinicians and researchers worldwide, today announced the start of a partnership with the Academic Centre on Rare Diseases (ACoRD) at University College Dublin. ACoRD will use NextCODE solutions to take full advantage of the latest sequencing technologies to improve the diagnosis and understanding of autism and rare diseases. These include NextCODE's Clinical Sequence Analyzer, to identify causal mutations in families with a range of rare disorders, and Sequence Miner and the GOR database infrastructure to mine whole-genome data for novel sequence variants linked to autism spectrum disorders.

NextCODE puts the world's most proven sequence analysis platform in the hands of clinicians and researchers around the globe, enabling them to use the full power of the genome to better diagnose and treat disease.

"This partnership is key to our strategy of building on ACoRD's reputation in rare genomics to establish ourselves as a centre of excellence in this field," said Dr Sean Ennis, director at ACoRD, UCD School of Medicine and Medical Science. "Sequencing is a powerful means to identify the causes of disease, but it requires the ability to efficiently store and query truly vast amounts of data. NextCODE's system has done this on an unparalleled scale, and can deliver diagnoses on a case-by case basis and enable large-scale discovery efforts."

Dr Ennis and his colleagues work and publish on a range of genetic diseases, with a particular recent focus on autism. He co-founded the Irish Autism Genetics Collaboration and sits on the research committee of the international Autism Genome Project. More recently he established a Research Centre dedicated to studying Rare Genetic Diseases.

"UCD is renowned as both a clinical and research organization, enabling them to exploit the breadth of our system's potential," said Jeffrey Gulcher, MD, PhD, president, CSO and co-founder of NextCODE. "We are very pleased that they have selected our platform to tackle their most challenging cases and to underpin the use of NGS in their ongoing diagnostics and gene discovery programs."

NextCODE puts the world's most proven sequence analysis platform in the hands of clinicians and researchers around the globe, enabling them to use the full power of NGS data to better diagnose and treat disease. Our solutions combine the only whole-genome analysis system proven at scale with access to the largest and most successful clinical genetics reference database in the world. That gives our partners accurate and actionable insights in real time, with the ability to exploit all their NGS data and visualize mutations at base-by-base resolution - right from their desktop. NextCODE is a private company headquartered in Cambridge, Massachusetts. Visit us on the web at nextcode.com.

Contact:
Edward Farmer
efarmer@nextcode.com
+1 781 775 6206

Photo - http://photos.prnewswire.com/prnh/20140706/124561

SOURCE NextCODE Health

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   
Autism

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES